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Abstract
Evidence is accumulating that non-anesthesiologist-administered propofol (NAAP) sedation has a
safety and efficacy profile comparable or superior to that provided by benzodiazepines with or
without opioids. The guidelines currently available emphasize the importance of appropriate patient
selection, staff training, monitoring, and low-dose sedation protocols for NAAP safety. In addition,
capnograph monitoring and computer-assisted sedation systems may further improve patient safety
during NAAP.
Introduction and context
Propofol (2,6 di-isopropyl phenol) is an ultra-short-
acting anesthetic agent that provides sedative and
amnestic effects at subanesthetic doses. It also has
some analgesic effects [1]. Owing to its unique pharma-
cokinetic properties, its clinical applications have
expanded since its introduction in the 1980s from the
induction and maintenance of anesthesia to include
monitored anesthesia care (MAC) and procedural seda-
tion. Although in most product information it is stated
that propofol should be administered only by anesthe-
siologists or persons with experience in intensive care,
the use of non-anesthesiologist-administered propofol
(NAAP) has dramatically increased, especially for gastro-
intestinal endoscopy [2].
Although such a potent anesthetic drug has well-known
cardiorespiratory side effects, there are data from non-
anesthesiologists suggesting that, using careful protocols,
training, and monitoring, propofol sedation has a safety
profile comparable to that of traditional sedation
(benzodiazepine or opioids or their combination) in
regard to the incidence of cardiopulmonary complica-
tions, airway interventions, or mortality [2-4]. NAAP
resulted in faster induction of sedation and much shorter
recovery times when compared with traditional sedation,
and the rate of patient satisfaction was superior or
equivalent [3,4]. Some endoscopists have even claimed
that NAAP exhibits a safety profile comparable to that of
general anesthesia or MAC and have questioned the cost-
effectiveness of anesthesiologist-administered sedation
in gastrointestinal endoscopy [2,3]. In contrast, some
anesthesiologists are worried that the use of propofol by
unqualified persons may be responsible for increased
complication rates [5]. One report concerning 153
deaths occurring after upper gastrointestinal endoscopy
points out that high-risk patients (American Society of
Anesthesiologists [ASA] III or higher) receiving intrave-
nous sedation were not adequately monitored, and most
of the deaths were attributed to the absence of an
anesthesiologist during the procedure [6]. Currently,
there are no studies directly comparing the safety and
efficacy of NAAP with those of anesthesiologist-adminis-
tered propofol sedation for gastrointestinal endoscopy or
bronchoscopy.
Propofol has a narrow therapeutic window and a
propensity to cause apnea, it also reduces airway muscle
tone, produces cardiovascular depression, and does not
have a reversal agent. In addition, sedation is a continuum
of states [7], and a transition from minimal sedation to
general anesthesia may occur inadvertently with a
relatively small alteration in dose. Thus, it is relatively
easy to induce oversedation and cardiopulmonary
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complications with propofol in endoscopic procedures
that last a relatively long time, thereby requiring repeated
doses or infusion of sedative agents, such as endoscopic
retrograde cholangiopancreatography (ERCP), particu-
larly in elderly high-risk patients. Although propofol
sedation was associated with lower postinterventional
hypoxemia and hepatic encephalopathy than benzodia-
zepines for older patients and patients with cardiore-
spiratory or liver disease [8,9], there is a report showing
that the safety of propofol sedation with careful
monitoring was comparable to that of a midazolam/
pethidine combination for routine ERCP in elderly high-
risk patients [10]. However, most guidelines or state-
ments now available state that NAAP is appropriate for
low- and average-risk patients undergoing elective endo-
scopic procedures [11-13] but that for high-risk patients
NAAP is not recommended and an anesthetist should be
available [12,13].
There has been a general increase in minimally invasive
surgery with a consequent demand for sedation services.
In many settings, a shortage of staff means that
anesthesiologists cannot provide services for all
requested procedures outside the operating theater.
Thus, NAAP appears to be a logical development for
many procedures, particularly those less complicated
ones such as screening gastrointestinal endoscopy.
However, owing to the sociocultural, economic, and
medico-legal differences that exist between countries,
controversy over the legality of NAAP and how to use it
safely and efficiently is still evident throughout the
world.
Recent advances
Many articles demonstrating safety with NAAP, whether
physician-administered or physician-directed nurse-
administered propofol sedation, have been published.
A recent multinational study of 646,080 gastrointestinal
endoscopy procedures (223,656 from 28 published
articles and 422,424 from 28 centers in 10 countries)
revealed a very low overall risk of cardiopulmonary
complications [2]. Of the 569,220 cases for which data
were available, only 0.1% required transient bag-mask
ventilation. The rates of bag-mask ventilation interven-
tion were much lower for colonoscopy than upper
endoscopy (0.01-0.10%). Endotracheal intubation, per-
manent neurologic injury, and death resulted in 11, 0,
and 4 cases, respectively. The overall death rate was lower
than the rate of reported deaths in cases sedated by
endoscopists using opioids and benzodiazepines (1 per
160,000 as opposed to 11 per 100,000) [14]. The four
patients who died all had severe coexisting diseases and
received non-routine upper endoscopy procedures.
Although the authors did not offer any information
about the other seven intubated cases, the results suggest
that NAAP can be performed safely for most gastro-
intestinal endoscopies but that those high-risk patients
or procedures would benefit from specialist anesthesio-
logist care.
Aside from offering a comparable safety profile, NAAP
provided a higher quality of sedation in terms of
neuropsychometric recovery and patient tolerance
[3,4,15-18]. Trummel and colleagues [15] used an
expert videotape analysis method to evaluate the patient
state during procedural sedation and found that
propofol provided much better procedural conditions
and greater patient satisfaction compared with a
midazolam/opioid combination. Clark and colleagues
[16] used the bispectral index (BIS) to direct propofol or
midazolam sedation in flexible bronchoscopy and
found that the induction time (the time required to
achieve the targeted BIS value of 70-85 after drug
injection) was similar in the two groups but that the
recovery time (from the end of the procedure to
recovery of BIS of greater than 90) was shorter in the
propofol group (5.4 ± 4.7 versus 11.7 ± 10.2 minutes).
The cognitive recovery evaluated by a continuous
performance test at 15 minutes after the procedure
also showed significant differences for all tested items in
favor of the propofol group [16]. Horiuchi and
colleagues [17] reported a clinical trial on nurse-
administered low-dose propofol sedation for diagnostic
esophagogastroduodenoscopy in 10,662 adults. Full
recovery, including consciousness and psychomotor
function, occurred in 99.9% of patients 60 minutes
after the procedure. Most surprisingly, some of the
patients even drove home after successful recovery with
the permission of their physician [17]. Owing to its
faster recovery profile, propofol sedation seems to
improve patient satisfaction, and the efficiency of
throughput also may be an economic advantage. It is
important to stress that these data come from low-dose
propofol sedation for relatively healthy individuals
(without severe comorbidity) who underwent standard
endoscopic procedures. The effect of propofol on
patients with more comorbidity and the effect of higher
doses of propofol (e.g., for longer-lasting interventional
endoscopic procedures) remain unclear and need
further research.
Since it is difficult to titrate single-agent propofol to
moderate sedation and difficult to prevent patient
movement or gagging during endoscopy, some endos-
copists preferred ‘balanced propofol sedation’ (BPS). BPS
combines propofol with a small dose of an opioid (e.g.,
fentanyl 50 mg) or a benzodiazepine (e.g., midazolam
1mg) or both [19]. It is reported that BPS is safer because
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propofol requirements are lower, it is easier to titrate to
moderate sedation, and it does not affect patient
recovery time or satisfaction. However, the author of
that report acknowledged that there is unquestionable
synergism in the sedative effects of propofol with both
opioids and benzodiazepines, thus the initial and
repeated doses of propofol should be decreased accord-
ingly and administered more carefully. Currently, there
are no data available to compare the neuropsychomotor
functional recovery after BPS to that of single-agent
propofol sedation, and whether BPS increases postinter-
ventional hypoxemia remains unclear. Randomized
clinical trials that are well-designed and more detailed
are needed to resolve these questions.
NAAP is usually done by giving repeated small-dose
boluses in the same fashion that other agents for
non-anesthesiologist-delivered sedation are given. The
computer-assisted target-controlled infusion (TCI) system
widely used by anesthesiologists in anesthesia and MAC
is seldom mentioned by non-anesthesiologists [12]. The
TCI system can automatically administer propofol
through a computer-regulated infusion pump to achieve
a particular target blood concentration. The dose and
infusion rate are calculated by the computer according to
previously validated three-compartment pharmacokinetic
data adjusted to take into account patient demographic
parameters (e.g., age, sex, height, and weight). The
potential advantage of the TCI method is to simplify
drug dosing andmaintain a stable drug concentration and
consequently a constant sedation depth. However, few
data comparing TCI and traditional propofol administra-
tion methods for endoscopy exist. Recently, a computer-
assisted personalized sedation system (Sedasys; Ethicon
Endo-Surgery, Inc., Cincinnati, OH, USA) in which
propofol dosing is adjusted by a computer according to
continuous physiologic monitoring has been developed.
It has been approved by the ASA for clinical use and is
indicated for minimal to moderate sedation in healthy
adult patients (ASA physical status I or II) undergoing
colonoscopy or esophagogastroduodenoscopy proce-
dures. This device may be helpful for NAAP safety, but
there are still very few data on its use [20].
As oxygen desaturation is actually a relatively late sign of
respiratory obstruction or depression, capnograph moni-
toring has been introduced to promote NAAP safety.
A recent study demonstrated that capnograph monitor-
ing of respiratory activity during NAAP improves patient
safety by reducing the frequency of hypoxemia, severe
hypoxemia, and apnea [21]. Another report showed that,
when the respiratory depression in adults receiving
emergency department procedural propofol sedation
was defined a priori as an ETCO2 (end-tidal carbon
dioxide) level of 50 mm Hg or greater, an absolute
increase or decrease from baseline of 10% or greater, or a
loss of waveform for 15 seconds or greater, the addition
of capnography to standard monitoring identified all
cases of hypoxia before onset, with the median time
from capnographic evidence of respiratory depression to
hypoxia being 60 seconds (range of 5-240 seconds) [22].
Capnography is worth recommending when it is difficult
to visually assess respiration or during prolonged
procedures such as ERCP and endoscopic ultrasound.
So far, there has been no technological advance that can
replace professional expertise. Important elements of
NAAP safety are a well-trained and appropriately qualified
person or team, strict adherence to clear guidelines,
and a cautious attitude. There are several different guide-
lines available for direct gastrointestinal endoscopist-
administered propofol sedation [7,12,13,23]. The
guidelines produced by the American Society for Gastro-
intestinal Endoscopy partially contradict those produced
by the ASA for sedation by non-anesthesiologists [7],
whereas the German [12] and Australian [13] guidelines
were developedwith the involvement of anesthesiologists.
However, the following issues are common to all four
guidelines: (a) the definition of the continuum of
sedation; (b) a structured preprocedure patient evaluation,
including informed consent for sedation; (c) standard
monitoring during sedation with pulse oximetry, electro-
cardiogram, non-invasive blood pressure, respiration, and
depth of sedation; and (d) special training of non-
anesthesiologist physicians or nurses in pharmacology,
complications recognition, and advanced life support,
including the skills of airway management, defibrillation,
and use of resuscitation drugs. The German and Australian
guidelines agree that NAAP should be limited to patients
of low and moderate risk, and the involvement of an
anesthesiologist is recommended for high-risk patients.
Both guidelines give a detailed definition of high-risk
patients, but there is some discrepancy in the actual
definitions. In the German guidelines, high-risk patients
include high ASA classification (III or IV) and difficult
endoscopic interventions or the presence of pathological-
anatomical features associated with a higher risk of airway
obstruction during the intervention [12]. In the Australian
guidelines, high-risk patients include (a) the elderly; (b)
patientswith severely limiting heart, cerebrovascular, lung,
liver, or renal disease, morbid obesity, significant obstruc-
tive sleep apnea or known or suspected difficult endo-
tracheal intubation, acute gastrointestinal bleeding with
cardiovascular compromise or shock, severe anemia, the
potential for aspiration of stomach contents (possibly
necessitating endotracheal intubation), or previous
adverse events due to sedation, analgesia, or anesthesia;
and (c) ASA grade IV or V patients [13]. The guidelines
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formulated by the American Society for Gastrointestinal
Endoscopy remain ambiguous with respect to the admin-
istration of sedation in ASA III or IV patients and state that
the benefit of involving anesthesiologists in ASA IV (or
higher) patients is unclear. This statement has been
strongly rejected by some anesthesiologists and may well
put high-risk patients at considerable risk [5]. A recent
statement by the American Gastroenterology Association
omits any recommendations on the administration of
sedation in ASA III or IV patients and only mentions that
the use of anesthesiologist-administered propofol for
healthy individuals undergoing elective endoscopy with-
out risk factors for sedation-related complications is very
costly. The statement also advised that units initiating a
propofol sedation program should do so under the
direction of an anesthesiologist [3].
Although there are a few studies indicating that NAAP
can be safely performed for bronchoscopy and some
emergency department procedures [4,16,22], much
fewer outcome data are available for these procedures,
and further research and audit are required before
making any recommendation.
It has been reported that a tripartite group (the
Australian and New Zealand College of Anesthetists,
the Gastroenterological Society of Australia, and the
Royal Australasian College of Surgeons, which conjointly
established the guidelines for Australia) is in the process
of establishing an endoscopist training program that
involves the use of didactic lectures, small group
discussions, anesthetic simulators, and observation
sessions in units already using NAAP [24]. Such training
programs are expected to legitimize NAAP and to help
endoscopists use propofol safely and may be used as an
example to other academic bodies.
Implications for clinical practice
Propofol use by non-anesthesiologists is likely to
become more common because of increased demand
by both patients and physicians and the increased
number of procedures being performed outside the
operating theater. If properly complied with, the various
guidelines may contribute to the safe application of
NAAP. Capnograph monitoring and computer-assisted
personalized systems for propofol administration may
help to prevent oversedation by non-anesthesiologists
but these systems warrant further evaluation. The
recovery time of propofol, especially the neuropsycho-
metric recovery time with low-dose propofol titrated to
moderate sedation, is much shorter than that of
traditional sedation methods and drugs. Whether con-
current use of benzodiazepines/opioids is of benefit
remains controversial and requires further evaluation.
Since propofol is very different from the more traditional
sedative agents used by non-anesthesiologists, the units
that are performing NAAP should be in close commu-
nication with anesthesiologists and make sure that
anesthesia expertise is immediately available.
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